机译:最初的高剂量氢化可的松(HDC)治疗21-羟化酶缺乏症(21-OHD)不会影响生命的前三年的线性增长
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;
21-hydroxylase deficiency; hydrocortisone; initial high-dose treatment; linear growth; newborn screening;
机译:最初的高剂量氢化可的松(HDC)治疗21-羟化酶缺乏症(21-OHD)不会影响生命的前三年的线性增长
机译:患有非典型21-羟化酶缺乏症(21-OHD)的婴儿和儿童被诊断为临床病程
机译:非经典的21-羟化酶缺乏症(21-OHD)患者的临床病历被诊断为婴儿和儿童
机译:先天性肾上腺素增生由于21羟化酶缺乏症的产前诊断和治疗范式
机译:情感计算对提高主观幸福感的影响及其对坚持和生活质量的影响:与Alpha-1抗胰蛋白酶缺乏症相关的COPD患者的经验。
机译:患者的生长相关特征18岁由于21-羟化酶缺乏(21Ohd):来自I-CAH登记处的现实世界证据
机译:婴儿期诊断出患有非染色21-羟化酶缺乏(21-OHD)患者的临床课程